A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease
Status and phase
Terminated
Phase 2
Conditions
Alzheimer's Disease
Treatments
Drug: ABT-089
Details and patient eligibility
About
The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.
Sex
All
Ages
50 to 85 years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Current diagnosis of probable Alzheimer's disease.
- ADAS-cog score of at least 12 and MMSE score of 10 to 26.
- Non-smoker
- Must have legally authorized representative and a reliable caregiver. The caregiver and legally authorized representative may be the same person.
- Fluent in English.
Exclusion criteria
- Use of cholinesterase inhibitors or any other drugs to treat Alzheimer's disease in the last 6 weeks.
- Has clinically significant or uncontrolled medical condition other than Alzheimer's disease.
- Nursing home resident.
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Crossover Assignment
Masking
Double Blind
Trial contacts and locations
8
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems